A Phase 1 interventional study of BIBF 1120 M + Pemetrexed and BIBF 1120 H + Pemetrexed in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Terminated at 3 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-03-06.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. nintedanib · Carcinoma, Non-Small-Cell Lung.
Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is the only one that started in 2009, is one of 9 in phase 1, and was the 3rd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:
China Medical University Hospital · Sites in Taiwan
Ages 20–70
By country, each count listing its studies:
nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 7 · Phase 3 3
First in 2005; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 16 across the 19 interventional studies. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 19 have an industry lead sponsor. The 8 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim: 3 open now, 5 under way, 1 of them phase 3. Of 60 finished, 53 (88%) have results posted.
Among the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, this one is the 37th largest by enrollment of the 49 interventional ones that give a count, is one of 6 that started in 2009, is one of 21 in phase 1, and was the 12th registered.
Boehringer Ingelheim’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 68 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The objectives of this trial are to estimate the following in Japanese patients with advanced NSCLC of stage IIIB/IV or with recurrence after failure of first-line chemotherapy.
Phase I part The objective of the phase I part is to define the Maximum Tolerated Dose (MTD) of BIBF 1120 at a dose level up to twice daily 200 mg with standard dose of pemetrexed (500 mg/m\^2) and to determine the Recommended Dose (RD) for the phase II part.
Phase II, to investigate the efficacy and safety of BIBF 1120 in combination with pemetrexed (500 mg/m\^2) as compared to pemetrexed (500 mg/m\^2) + placebo
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who have sufficient baseline organ function over 4 weeks and whose laboratory data meet the following criteria at the enrolment
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase I part: Find MTD by using low, medium or high BIBF 1120 twice daily and 500mg/m\^2 pemetrexed once every 3 weeks
Drug: BIBF 1120 M + Pemetrexed · Drug: BIBF 1120 H + Pemetrexed · Drug: BIBF 1120 L + Pemetrexed
PHase II part: Study arm
Drug: BIBF 1120 RD + Pemetrexed
Phase II part: Comparator arm
Drug: BIBF 1120 Placebo + Pemetrexed
Drug pages: Nintedanib · Pemetrexed
BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m\^2
Drug pages: Nintedanib · Pemetrexed
BIBF 1120 high dose bid+ Pemetrexed 500 mg/m\^2
Drug pages: Nintedanib · Pemetrexed
confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m\^2
Drug pages: Nintedanib · Pemetrexed
BIBF 1120 low dose bid+ Pemetrexed 500 mg/m\^2
placebo BIBF 1120 bid + Pemetrexed 500 mg/m\^2
Dose Limiting Toxicities
Number of participants with dose limiting toxicity (DLT) in combination therapy of BIBF 1120 and pemetrexed during the first course
Time frame: During the first course, 21 days
Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 for All Courses
Number of patients with adverse events according to worst Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 for all courses. CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE) or 5 (death related to AE).
Time frame: Between first administration of pemetrexed and 28 days after last administration of pemetrexed and/or BIBF 1120, up to 1020 days
Overall Response Rate
Number of participants with complete response (CR) or partial response (PR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0
Time frame: Every 6 weeks after start of study treatment until end of treatment, up to 992 days
Disease Control Rate
Number of participants with complete response (CR), partial response (PR) or stable disease (SD) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0
Time frame: Every 6 weeks after start of study treatment until end of treatment, up to 992 days
Duration of Disease Control
Duration of disease control was defined as the time period from the first study drug administration to the progressive disease (PD) or death of patients, whichever occurred earlier.
Time frame: From first study drug administration until PD or death, up to 1003 days
Number of Participants With Clinically Relevant Abnormalities in Laboratory Parameters
Number of participants with clinically relevant abnormalities in laboratory parameters reported as adverse events which occurred in \>= 20% of patients
Time frame: Between first administration of pemetrexed and 28 days after last administration of pemetrexed and/or BIBF 1120, up to 1020 days
AUC0-inf of Nintedanib
Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)
Time frame: 5 minutes (min) before nintedanib administration and 1h, 2h, 3h, 4h, 6h, 7h, 10h and 23h 55min after nintedanib administration in cycle 1
Cmax of Nintedanib
Maximum measured concentration of nintedanib in plasma (Cmax)
Time frame: 5 minutes (min) before nintedanib administration and 1h, 2h, 3h, 4h, 6h, 7h, 10h and 23h 55min after nintedanib administration in cycle 1
AUC0-inf of Pemetrexed
Area under the concentration-time curve of pemetrexed in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)
Time frame: 5 minutes (min) before pemetrexed administration and 10min, 40min, 1 hour (h), 2h, 4h, 6h, 23h 55min, 47h 55min after pemetrexed administration in cycles 1 and 2
Cmax of Pemetrexed
Maximum measured concentration of pemetrexed in plasma (Cmax)
Time frame: 5 minutes (min) before pemetrexed administration and 10min, 40min, 1 hour (h), 2h, 4h, 6h, 23h 55min, 47h 55min after pemetrexed administration in cycles 1 and 2
| Milestone | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 |
|---|---|---|---|
| Started | 3 | 6 | 9 |
| Completed | 0 | 0 | 0 |
| Not completed | 3 | 6 | 9 |
| Withdrew: Progressive disease | 3 | 1 | 5 |
| Withdrew: Dose limiting toxicity | 0 | 3 | 2 |
| Withdrew: Adverse event | 0 | 2 | 2 |
| Milestone | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 |
|---|---|---|---|
| Started | 0 | 2 | 1 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 2 | 1 |
| Withdrew: Progressive disease | 0 | 2 | 1 |
Number of participants with dose limiting toxicity (DLT) in combination therapy of BIBF 1120 and pemetrexed during the first course
| Participants | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 |
|---|---|---|---|
| Dose Limiting Toxicities | 0 | 1 | 2 |
Number of patients with adverse events according to worst Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 for all courses. CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE) or 5 (death related to AE).
| participants | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 |
|---|---|---|---|
| Grade 1 | 0 | 0 | 1 |
| Grade 2 | 2 | 1 | 2 |
| Grade 3 | 1 | 5 | 5 |
| Grade 4 | 0 | 0 | 1 |
| Grade 5 | 0 | 0 | 0 |
Number of participants with complete response (CR) or partial response (PR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0
| Participants | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 |
|---|---|---|---|
| Complete response | 0 | 0 | 0 |
| Partial response | 0 | 1 | 1 |
Number of participants with complete response (CR), partial response (PR) or stable disease (SD) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0
| Participants | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 |
|---|---|---|---|
| Disease Control Rate | 2 | 4 | 6 |
Duration of disease control was defined as the time period from the first study drug administration to the progressive disease (PD) or death of patients, whichever occurred earlier.
| Days | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 |
|---|---|---|---|
| Duration of Disease Control | 248.5 (162 to 335) | 228.5 (168 to 587) | 149.0 (121 to 1003) |
Number of participants with clinically relevant abnormalities in laboratory parameters reported as adverse events which occurred in \>= 20% of patients
| participants | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 |
|---|---|---|---|
| Alanine aminotransferase increased | 2 | 6 | 8 |
| Gamma-glutamyltransferase increased | 2 | 5 | 8 |
| Aspartate aminotransferase increased | 2 | 5 | 7 |
| Lymphocyte count decreased | 2 | 1 | 2 |
| Neutrophil count decreased | 2 | 3 | 4 |
| White blood cell count decreased | 2 | 2 | 3 |
| Blood alkaline phosphatase increased | 0 | 1 | 4 |
| Blood albumin decreased | 0 | 1 | 3 |
| Haemoglobin decreased | 1 | 1 | 3 |
Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)
| ng*h/mL | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 |
|---|---|---|---|
| AUC0-inf of Nintedanib | 105 ± 25.5 | 232 ± 60.5 | 323 ± 28.8 |
Maximum measured concentration of nintedanib in plasma (Cmax)
| ng/mL | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 |
|---|---|---|---|
| Cmax of Nintedanib | 20.5 ± 31.0 | 37.9 ± 71.7 | 55.1 ± 29.6 |
Area under the concentration-time curve of pemetrexed in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)
| ng*h/mL | Pemetrexed 500 mg/m2 |
|---|---|
| Cycle 1 | 194000 ± 19.9 |
| Cycle 2 (N=11) | 200000 ± 15.9 |
Maximum measured concentration of pemetrexed in plasma (Cmax)
| ng/mL | Pemetrexed 500 mg/m2 |
|---|---|
| Cycle 1 | 139000 ± 16.5 |
| Cycle 2 (N=11) | 149000 ± 15.4 |
Collected over Between first administration of pemetrexed and 28 days after last administration of pemetrexed and/or BIBF 1120, up to 1020 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | — | 1/3 (33.3%) | 3/3 (100%) |
| BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | — | 0/6 (0%) | 6/6 (100%) |
| BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 | — | 1/9 (11.1%) | 9/9 (100%) |
| Event | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 |
|---|---|---|---|
| FatigueGeneral disorders | 1/3 | 0/6 | 0/9 |
| HypercalcaemiaMetabolism and nutrition disorders | 1/3 | 0/6 | 0/9 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/3 | 0/6 | 1/9 |
| Event | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 2/3 | 6/6 | 8/9 |
| Gamma-glutamyltransferase increasedInvestigations | 2/3 | 5/6 | 8/9 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 5/6 | 7/9 |
| Aspartate aminotransferase increasedInvestigations | 2/3 | 5/6 | 7/9 |
| RashSkin and subcutaneous tissue disorders | 1/3 | 5/6 | 3/9 |
| ConstipationGastrointestinal disorders | 2/3 | 1/6 | 1/9 |
| NauseaGastrointestinal disorders | 2/3 | 3/6 | 4/9 |
| StomatitisGastrointestinal disorders | 2/3 | 2/6 | 1/9 |
| VomitingGastrointestinal disorders | 2/3 | 1/6 | 4/9 |
| FatigueGeneral disorders | 2/3 | 4/6 | 1/9 |
Treated set: all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment
| Age, Continuous(years) | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 | Total |
|---|---|---|---|---|
| Median | 61.0 (60 to 66) | 66.0 (54 to 70) | 64.0 (30 to 70) | 64.0 (30 to 70) |
| Sex: Female, Male(Participants) | BIBF 1120 100 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 150 mg + Pemetrexed 500 mg/m^2 | BIBF 1120 200 mg + Pemetrexed 500 mg/m^2 | Total |
|---|---|---|---|---|
| Female | 1 | 2 | 1 | 4 |
| Male | 2 | 4 | 8 | 14 |
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Oct 2009 to primary completion in Feb 2015, 64 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nintedanib · Pemetrexed
Carcinoma, Non-Small-Cell Lung →